Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls

Precursors of pancreatic cancer arise in the ductal epithelium; markers exfoliated into pancreatic juice might be used to detect high-grade dysplasia (HGD) and cancer. Specific methylated DNA sequences in pancreatic tissue have been associated with adenocarcinoma. We analyzed these methylated DNA markers (MDMs) in pancreatic juice samples from patients with pancreatic ductal adenocarcinomas (PDACs) or intraductal papillary mucinous neoplasms (IPMNs) with HGD (cases), and assessed their ability to discriminate these patients from individuals without dysplasia or with IPMNs with low-grade dysplasia (IPMN-LGD) (controls).
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research

Related Links:

In this study, the expression profiles of circRNAs from 10 PDAC tissues and their paired adjacent nontumor tissues were analyzed through RNA sequencing analysis. An enrichment analysis was employed to predict the functions of the differentially expressed circRNAs. Sequence alignment information and mRNA microarray projects were used to predict the RNA regulatory network. The knockdown of circRNAs by small interfering RNAs followed by wound healing and western blot assays was used to confirm their functions in a PDAC cell line. A total of 278 circRNAs were identified as differentially expressed in PDAC tissue. Of these, we ...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Publication date: 20 August 2019Source: Cell Reports, Volume 28, Issue 8Author(s): Adam L. Burrack, Ellen J. Spartz, Jackson F. Raynor, Iris Wang, Margaret Olson, Ingunn M. StromnesSummaryPancreatic ductal adenocarcinoma (PDA) is a lethal cancer resistant to immunotherapy. We create a PDA mouse model and show that neoantigen expression is required for intratumoral T cell accumulation and response to immune checkpoint blockade. By generating a peptide:MHC tetramer, we identify that PDA induces rapid intratumoral, and progressive systemic, tumor-specific T cell exhaustion. Monotherapy PD-1 or PD-L1 blockade enhance...
Source: Cell Reports - Category: Cytology Source Type: research
In the era of skyrocketing health care costs, measuring value in the hospital setting has become crucial. Pancreatic cancer, a notoriously aggressive disease with complex management, has in recent years been aggregated to specialized medical centers. In this issue of JAMA Surgery, Bateni et al present a review of outcomes and cost after attempted curative resection for early-stage pancreatic adenocarcinoma. Data were obtained from the California Cancer Registry along with the Office of Statewide Hospital Planning and Development. Consistent with previous reports, the study showed that high-volume and National Cancer Instit...
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
Conclusions The present propensity-matched analysis showed a significant association with survival for earlier delivery of chemotherapy in the adjuvant setting.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
Conclusions In tumor cells, MCT1 expression is associated with better prognosis and reduced nodal metastasis in pancreatic cancer, contrary to findings of past in vitro studies. Conversely, MCT4 expression in CAFs is indicative of worse prognosis.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
Sialyl Lewis A (sLeA, also known as CA19-9), a tetrasaccharide selectively and highly expressed on advanced adenocarcinomas including colon, stomach, and pancreatic cancers, has long been considered as an attractive target for active and passive vaccination. While progress in antibodies targeting tumor-associated protein antigens resulted in an impressive array of therapeutics for cancer treatment, similar progress in exploiting tumor-associated carbohydrate antigens, such as sLeA, has been hampered by the lack of a detailed understanding of the singular characteristics of these antigens. We have addressed this issue by an...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Conditions:   Pancreatic Adenocarcinoma;   Esophageal Adenocarcinoma;   Esophageal Squamous Cell Carcinoma;   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Triple Negative Breast Cancer;   Castration-resistant Prostate Cancer;   Microsatellite Stable Colorectal C ancer Interventions:   Drug: GB1275;   Drug: nab-paclitaxel and gemcitabine;   Drug: pembrolizumab Sponsor:   GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Semin intervent Radiol 2019; 36: 203-212 DOI: 10.1055/s-0039-1693118Interventional radiologists have multiple points of involvement in the treatment and management of patients with pancreatic adenocarcinoma. There is increasing interest in cytoreductive treatment of the primary tumor as well as metastatic disease via arterial and ablative techniques. The focus of this article is on the current evidence for pancreatic irreversible electroporation. For patients undergoing curative surgery or terminal palliation, interventional radiology can manage complications and symptoms. In this article, therapeutic and palliative option...
Source: Seminars in Interventional Radiology - Category: Radiology Authors: Tags: Review Article Source Type: research
Authors: Strand MS, Krasnick BA, Pan H, Zhang X, Bi Y, Brooks C, Wetzel C, Sankpal N, Fleming T, Goedegebuure SP, DeNardo DG, Gillanders WE, Hawkins WG, Wickline SA, Fields RC Abstract Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However, no direct RAS inhibitors exist for cancer therapy. Furthermore, the delivery of therapeutic agents of any kind to PDAC in particular has been hindered by the extensive desmoplasia and resultant drug delivery challenges that accompanies these tumors. Small interfer...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Gastroenterology | Pancreas | Pancreatic Cancer